S65pre-(baseline) and 12-month post-(follow-up) index hospitalization were included. Patients who had previous evidence of ACS or prescription of antiplatelet agents during baseline period or had major adverse cardiovascular events within the initial 30 days after discharge were excluded. Patients who had a ≥ 80% proportion of days covered (PDC) were considered adherent, while patients who had no gaps of ≥ 30 days in antiplatelet therapy were considered persistent. Logistic and Cox models were used to explore the associated factors for adherence and persistence, respectively. ReSultS: 5,486 patients (63.2±10.8 years; 60.2% male) were identified. Only 10.9% (N= 600) of them were adherent to antiplatelet agents during follow-up, and the mean PDC was 0.39±0.29 for the total cohort. 90.1% (N= 4,942) patients discontinued antiplatelet agents during follow-up and the average time to discontinuation was 103.89±110.27 days. Male, patients who received percutaneous coronary intervention (PCI) or those who had longer stay during index hospitalization had better adherence (Odds ratio [95%
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.